Scientific Article
previous document  unige:78459  next document
add to browser collection

Interleukin-1 blockade in refractory giant cell arteritis

Ly, Kim-Heang
Liozon, Eric
Michel, Marc
Fain, Olivier
Fauchais, Anne-Laure
Published in Joint bone spine. 2014, vol. 81, no. 1, p. 76-78
Abstract Giant cell arteritis is a primary large-vessel vasculitis characterized by an arterial wall inflammation associated with intimal hyperplasia leading to arterial occlusion. Glucocorticoids remain the mainstay of giant cell arteritis treatment. However, relapses and glucocorticoid-related complications are frequent and therapeutic options for refractory giant cell arteritis are quite limited. Like tumor necrosis factor-α and interleukin-6, interleukin-1β is also highly expressed in inflamed arterial walls of patients with giant cell arteritis and may contribute in the pathogenesis of this disease. We report treatment of three cases of refractory giant cell arteritis successfully treated with anakinra, an interleukin-1 blockade therapy. Anakinra was effective for all patients, yielding improvement in their inflammation biomarkers and/or in their symptoms, as well as a disappearance of arterial inflammation in PET/CT for two of them.
Keywords AgedAged, 80 and overAntirheumatic Agents/therapeutic useFemaleGiant Cell Arteritis/drug therapy/radionuclide imagingGlucocorticoids/therapeutic useHumansInterleukin 1 Receptor Antagonist Protein/therapeutic useInterleukin-1/antagonists & inhibitorsMalePositron-Emission Tomography
PMID: 23890680
Full text
Article (Published version) (798 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)
(ISO format)
LY, Kim-Heang et al. Interleukin-1 blockade in refractory giant cell arteritis. In: Joint bone spine, 2014, vol. 81, n° 1, p. 76-78. doi: 10.1016/j.jbspin.2013.06.004

425 hits

0 download


Deposited on : 2015-12-09

Export document
Format :
Citation style :